Crewe Advisors’s BioAtla BCAB Stock Holding History

Crewe Advisors’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-7	Closed	-$925	–	887
2023 Q1	$925	Hold	7	–	–	﹤0.01%	758
2022 Q4	$2.85K	Hold	7	–	–	﹤0.01%	778
2022 Q3	$3K	Hold	7	–	–	﹤0.01%	937
2022 Q2	$1K	Buy	+7	New	+$1.11K	﹤0.01%	1046

Other funds holding BCAB

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Crewe Advisors's BCAB Position: Q2 2023 in Review

Crewe Advisors sold out of BioAtla (BCAB) in Q2 2023, closing a stake of 7 shares — an estimated $925 sold.

Crewe Advisors first reported a position in BCAB in Q2 2022 and held it in 4 quarters. The position peaked at $3K in Q3 2022. 87 funds tracked by Wall St. Rank hold BCAB as of Q2 2023.

Crewe Advisors reported no remaining BioAtla position as of Q2 2023 after selling out during the quarter.
Crewe Advisors sold 7 BioAtla shares in Q2 2023, an estimated $925.
Crewe Advisors first reported a position in BioAtla in Q2 2022 and held it in 4 quarters.
Crewe Advisors's BioAtla position peaked at $3K in Q3 2022.
87 funds tracked by Wall St. Rank held BioAtla as of Q2 2023.

Based on Crewe Advisors's 13F filing for Q2 2023, filed 28 Jul 2023.